United States News Todas as matérias

Merck (NYSE:MRK) has secured a landmark regulatory approval in the European Union for its blockbuster immunotherapy Keytruda, marking the region’s first PD-1 inhibitor authorized to treat a particularly aggressive form of ovarian cancer.

Adagene (NASDAQ:ADAG) reported updated clinical data for its lead "SAFEbody" candidate, muzastotug, revealing a significant dose-dependent response in patients with treatment-resistant colorectal cancer—a population that has traditionally been unresponsive to immunotherapy.

Classover (NASDAQ:KIDZ), an AI-powered education technology company, reported its full-year 2025 financial results.

Namib Minerals (NASDAQ:NAMM) reported a resilient fiscal 2025 performance, characterized by rising profitability and steady progress on its multi-asset growth strategy in Zimbabwe, despite a slight dip in annual gold production.

ScottsMiracle-Gro (NYSE:SMG) has reaffirmed its fiscal 2026 financial guidance, signaling confidence in its margin recovery plan by highlighting a supply chain largely insulated from international volatility and inflationary spikes.

Adagene (NASDAQ:ADAG) and Incyte (NASDAQ:INCY) have entered into a clinical trial collaboration to evaluate a potent combination of immunotherapy agents in patients with microsatellite stable colorectal cancer (MSS CRC), a disease state notoriously resistant to standard immune checkpoint inhibitors.

AstraZeneca (NASDAQ:AZN) announced positive high-level results from its EMERALD-3 Phase III trial, demonstrating that a novel combination of immunotherapies and targeted treatment significantly improved outcomes for patients with the most common form of liver cancer.

Pharvaris (NASDAQ:PHVS) is moving toward its first regulatory filing in the first half of 2026, supported by a strong cash position and pivotal clinical successes for its lead candidate, deucrictibant.

Merck (NYSE:MRK) has officially moved its lead ophthalmology candidate into late-stage development, initiating a pivotal Phase 2b/3 trial for MK-8748 just two years after the pharmaceutical giant’s $3 billion acquisition of EyeBio.

Lindsay (NYSE:LNN) reported a sharp decline in second-quarter profitability as a contraction in both its agricultural and infrastructure segments weighed on the top line, leading to a more than 50% drop in net earnings.

Trimble (NASDAQ:TRMB) has moved to deepen its artificial intelligence capabilities within the construction sector, announcing an agreement to acquire Document Crunch, a provider of AI-powered contract intelligence and risk management tools.

AirSculpt Technologies (NASDAQ:AIRS), a national provider of body contouring procedures, reported its fourth-quarter and full-year fiscal 2025 financial results.

Transocean (NYSE:RIG) has fortified its financial position through a dual-track strategy of aggressive backlog expansion and balance sheet deleveraging, announcing approximately $1 billion in new contract awards alongside the full retirement of a high-interest bond series.

Acuity Brands (NYSE:AYI) reported a surge in second-quarter profitability and rewarded shareholders with an 18% dividend hike, as the company’s expansion into intelligent infrastructure compensated for a leaner performance in its core lighting segment.

Cheche Group (NASDAQ:CCG) reported its unaudited financial results for the second half and full year ended December 31, 2025, on Thursday, April 2, 2026.

Futu Holdings (NASDAQ:FUTU) announced on Thursday, April 2, 2026, that its board of directors has approved a significant cash dividend, signaling strong confidence in the company’s capital position following a historic 2025 fiscal year.

Priovant Therapeutics, a majority-owned subsidiary of Roivant Sciences (NASDAQ:ROIV), provided a significant update on its late-stage immunology pipeline on Thursday, April 2, 2026.

Roivant Sciences (NASDAQ:ROIV) provided a comprehensive clinical and regulatory update on Thursday, April 2, 2026, revealing a bifurcated path for its most advanced autoimmune programs.

Immunovant (NASDAQ:IMVT) announced topline results from two Phase 3 clinical studies evaluating batoclimab in patients with active, moderate-to-severe thyroid eye disease (TED) on Thursday, April 2, 2026.

Dogness (NASDAQ:DOGZ) reported its financial results for the six months ended December 31, 2025, on Thursday, April 2, 2026.

Faraday Future Intelligent Electric (NASDAQ:FFAI) announced its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, April 2, 2026.

DuPont (NYSE:DD) announced the successful completion of the divestiture of its Aramids business to Arclin on Wednesday, April 1, 2026.

Conagra Brands (NYSE:CAG) reported financial results for the third quarter of fiscal 2026, ended February 22, 2026, on Wednesday, April 1.

Axsome Therapeutics (NASDAQ:AXSM) announced on Wednesday, April 1, 2026, that it has acquired exclusive global rights to balipodect (formerly TAK-063) from Takeda Pharmaceutical Company.